Ajanta Pharma Ltd. reported an 11% year-on-year increase in profit after tax (PAT) for the quarter ended March 31, 2025, at ₹225 crore, compared to ₹203 crore in the same period last year. Revenue from operations rose 11% YoY to ₹1,170 crore, supported by robust growth across branded generics and US business segments. EBITDA came in at ₹297 crore, up 7% YoY, with EBITDA margin steady at 25%. PAT margin stood at 19% for the quarter.
For the full financial year FY25, Ajanta Pharma reported a 13% increase in PAT to ₹920 crore, while revenue from operations rose 10% to ₹4,648 crore. EBITDA for the year rose 7% to ₹1,260 crore, translating to a margin of 25%. Cash flow from operations (CFO) stood at ₹1,157 crore with an impressive EBITDA-to-CFO conversion rate of 92%. Free cash flow (FCF) was ₹694 crore, reflecting a 75% FCF-to-PAT conversion. The company reported a return on capital employed (ROCE) of 32% and return on net worth (RONW) of 25%.
During the fiscal, Ajanta distributed ₹700 crore to shareholders — ₹349 crore as dividend and ₹351 crore via buyback — translating to a 76% PAT payout.
On a segmental basis, branded generics revenue for Q4FY25 grew 13% in India, 8% in Asia, and 17% in Africa. For the full year, branded generics revenue rose 15% YoY to ₹3,394 crore. The US generics business grew 9% YoY to ₹1,047 crore in FY25. However, the Africa institutional business declined 41% YoY to ₹147 crore, pulling down overall institutional contribution.
The company remains confident in its growth trajectory, led by branded generics and strategic expansion in regulated markets.
